Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124602
Filing Date
2024-11-12
Accepted
2024-11-12 07:43:31
Documents
67
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q pyxs-20240930.htm   iXBRL 10-Q 2161267
2 EX-31.1 pyxs-ex31_1.htm EX-31.1 15238
3 EX-31.2 pyxs-ex31_2.htm EX-31.2 15243
4 EX-32.1 pyxs-ex32_1.htm EX-32.1 8936
5 EX-32.2 pyxs-ex32_2.htm EX-32.2 8293
6 GRAPHIC img32424975_0.jpg GRAPHIC 122064
  Complete submission text file 0000950170-24-124602.txt   7984192

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20240930.xsd EX-101.SCH 1345336
69 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20240930_htm.xml XML 956191
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40881 | Film No.: 241443372
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)